Show Indication & Important Safety InformationARICEPT is indicated for the treatment of dementia of the Alzheimer's type. Efficacy has been demonstrated in patients with mild, moderate, and severe Alzheimer's disease (AD).
Dosing information
The indicated doses are: 5 mg/day for mild to moderate AD; 10 mg/day for mild, moderate, and severe AD; and 23 mg/day for moderate to severe AD.
The recommended starting dose of ARICEPT is 5 mg/day. A dose of 10 mg/day can be administered once patients have been on 5 mg/day for 4 to 6 weeks; 23 mg/day can be administered once patients have been on 10 mg/day for at least 3 months.
ARICEPT® (donepezil HCl)
Featured Information
ARICEPT (donepezil HCl) 23 mg/day - A new dose of ARICEPT NOW APPROVED for patients with moderate to severe Alzheimer's diseaseIn a large, head-to-head trial of over 1400 patients with moderate to severe Alzheimer's disease, the efficacy of ARICEPT 23 mg/day was compared to ARICEPT 10 mg/day. 
View the head-to-head clinical study
Please see important prescribing and patient information |
ARICEPT Indication and Important Safety Information
Please scroll to see the Indication below.
IMPORTANT SAFETY INFORMATION
ARICEPT, a cholinesterase inhibitor, has the potential to increase gastric acid secretion. Patients at risk for developing ulcers, including those receiving concurrent NSAIDs, should be monitored closely for gastrointestinal bleeding.
Syncopal episodes have been reported in association with the use of ARICEPT.
ARICEPT should be used cautiously in patients undergoing anesthesia and with certain preexisting conditions, such as bradycardia, seizure disorder, asthma/chronic obstructive pulmonary disease, and bladder outflow disorders, as cholinesterase inhibitors have the potential to exacerbate these conditions.
The use of ARICEPT 23 mg/day is associated with weight loss. Consideration should be given when prescribing ARICEPT 23 mg/day to patients of lower weight.
In clinical trials, the most common adverse events seen with ARICEPT were nausea, diarrhea, insomnia, vomiting, muscle cramps, fatigue, and anorexia. The incidence of nausea and vomiting was markedly greater in patients taking ARICEPT 23 mg/day vs patients continued on ARICEPT 10 mg/day.
Indication
ARICEPT is indicated for the treatment of dementia of the Alzheimer's type. Efficacy has been demonstrated in patients with mild, moderate, and severe Alzheimer's disease (AD).
Dosing information
The indicated doses are: 5 mg/day for mild to moderate AD; 10 mg/day for mild, moderate, and severe AD; and 23 mg/day for moderate to severe AD.
The recommended starting dose of ARICEPT is 5 mg/day. A dose of 10 mg/day can be administered once patients have been on 5 mg/day for 4 to 6 weeks; 23 mg/day can be administered once patients have been on 10 mg/day for at least 3 months.